Parameters Included in the Univariable Prognostic Factor Analysis
| Patient data | |
| Age (yr) | |
| Sex (male/female) | |
| Obesity index (body weight/ideal body weight) | |
| Body surface (m2) | |
| CMV serology (+/−) | |
| Disease data | |
| Type of leukemia (AML, ALL, Hybrid AL) | |
| History of extramedullary involvement (yes/no) | |
| WBC count at diagnosis (×109/L) | |
| Cytogenetics at diagnosis (unfavorable/others) | |
| Immunophenotyping of ALL (B-lineage/T-lineage) | |
| First remission duration (months) | |
| Chemotherapy courses to last remission (1, 2, >2) | |
| Treatment after relapse (treated/untreated) | |
| Leukemia at BMT (marrow/extramedullary/both) | |
| WBC count at BMT (×109/L) | |
| BM blasts at BMT (%) | |
| Blasts in PB at BMT (×109/L) | |
| Disease stage at BMT (primary induction failure, remission, | |
| relapse) | |
| Donor data | |
| Age (yr) | |
| Sex (male/female) | |
| Parity of the female donor (yes/no) | |
| CMV serology (+/−) | |
| Transplant data | |
| Yr of transplant | |
| Interval between last remission and BMT (mo) | |
| HLA-matching (matched, mismatched) | |
| TBI dose (cGy) | |
| Marrow cell dose (nucleated cells/kg) | |
| Granulocyte-macrophage colony-stimulating factor (yes/no) | |
| GVHD prophylaxis (MTX + CSP/others) | |
| Laminar air flow isolation (yes/no) |
| Patient data | |
| Age (yr) | |
| Sex (male/female) | |
| Obesity index (body weight/ideal body weight) | |
| Body surface (m2) | |
| CMV serology (+/−) | |
| Disease data | |
| Type of leukemia (AML, ALL, Hybrid AL) | |
| History of extramedullary involvement (yes/no) | |
| WBC count at diagnosis (×109/L) | |
| Cytogenetics at diagnosis (unfavorable/others) | |
| Immunophenotyping of ALL (B-lineage/T-lineage) | |
| First remission duration (months) | |
| Chemotherapy courses to last remission (1, 2, >2) | |
| Treatment after relapse (treated/untreated) | |
| Leukemia at BMT (marrow/extramedullary/both) | |
| WBC count at BMT (×109/L) | |
| BM blasts at BMT (%) | |
| Blasts in PB at BMT (×109/L) | |
| Disease stage at BMT (primary induction failure, remission, | |
| relapse) | |
| Donor data | |
| Age (yr) | |
| Sex (male/female) | |
| Parity of the female donor (yes/no) | |
| CMV serology (+/−) | |
| Transplant data | |
| Yr of transplant | |
| Interval between last remission and BMT (mo) | |
| HLA-matching (matched, mismatched) | |
| TBI dose (cGy) | |
| Marrow cell dose (nucleated cells/kg) | |
| Granulocyte-macrophage colony-stimulating factor (yes/no) | |
| GVHD prophylaxis (MTX + CSP/others) | |
| Laminar air flow isolation (yes/no) |
Abbreviations: AL, acute leukemia; ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; BM, bone marrow; BMT, bone marrow transplant; CMV, cytomegalovirus; CSP, cyclosporine; CT, chemotherapy; GVHD, graft-versus-host disease; MTX, methotrexate; PB, peripheral blood; TBI, total body irradiation; WBC, white blood cells.